11:04 AM EDT, 06/03/2025 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday the European Commission approved Adcetris in combination with a chemotherapy regimen to treat patients with stage 2b, 3 and 4 Hodgkin lymphoma.

The Commission's approval follows a recommendation from the Committee for Medicinal Products for Human Use on April 25, according to a statement.

The approval is based on the phase 3 HD21 trial, which achieved its co-primary safety and efficacy endpoints, the company said.

It added that the development marks the second approval for the drug regimen for the treatment of Hodgkin lymphoma.

Price: 14.99, Change: -0.09, Percent Change: -0.60